Shots:

• Jazz to acquire GW Pharmaceuticals for $220/ GW ADS- out of which $200 in cash and $20 in Jazz ordinary shares- making a total deal value $7.2B with a 50% premium over a GW's closing stock price on Feb 2- 2021. The transaction expected to close in Q2’21
• The acquisition will expand Jazz’ neuroscience portfolio and expand its footprints with the addition of Epidiolex which is the first and only FDA-approved prescription cannabidiol medicine
• Apart from Epidiolex- GW’s pipeline includes nabiximol for spasticity associated with MS and spinal cord injury as well as earlier-stage cannabinoid therapies for autism and schizophrenia

 ­ Ref: PRNewswire | Image: Cannin